These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36620892)

  • 21. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
    Tassorelli C; Onishchenko K; Halker Singh RB; Duan M; Dupont-Benjamin L; Hemstock M; Voller C; McAllister P; Nahas SJ; Gandhi P; Ailani J
    Cephalalgia; 2024 Feb; 44(2):3331024241235156. PubMed ID: 38410850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
    Sakai F; Suzuki N; Ning X; Ishida M; Usuki C; Iba K; Isogai Y; Koga N
    Drug Saf; 2021 Dec; 44(12):1355-1364. PubMed ID: 34687446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents.
    Apostol G; Pakalnis A; Laforet GA; Robieson WZ; Olson E; Abi-Saab WM; Saltarelli M
    Headache; 2009 Jan; 49(1):36-44. PubMed ID: 19040678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults.
    Min KC; Kraft WK; Bondiskey P; Colón-González F; Liu W; Xu J; Panebianco D; Mixson L; Dockendorf MF; Matthews CZ; Boinpally R
    Clin Transl Sci; 2021 Mar; 14(2):599-605. PubMed ID: 33142014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
    Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM
    Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study.
    Boinpally R; McGeeney D; Borbridge L; Trugman J
    Clin Pharmacol Drug Dev; 2023 Oct; 12(10):1013-1021. PubMed ID: 37210713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial.
    Boinpally R; Spaventa J; Chen K; Butler M
    Clin Drug Investig; 2021 Jun; 41(6):557-567. PubMed ID: 33948911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atogepant for the prevention of episodic migraine in adults.
    Switzer MP; Robinson JE; Joyner KR; Morgan KW
    SAGE Open Med; 2022; 10():20503121221128688. PubMed ID: 36226229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
    Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
    Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.
    Dodick DW; Goadsby PJ; Silberstein SD; Lipton RB; Olesen J; Ashina M; Wilks K; Kudrow D; Kroll R; Kohrman B; Bargar R; Hirman J; Smith J;
    Lancet Neurol; 2014 Nov; 13(11):1100-1107. PubMed ID: 25297013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term migraine prevention with topiramate: open-label extension of pivotal trials.
    Rapoport A; Mauskop A; Diener HC; Schwalen S; Pfeil J
    Headache; 2006; 46(7):1151-60. PubMed ID: 16866719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
    Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
    J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
    Ashina M; Goadsby PJ; Reuter U; Silberstein S; Dodick D; Rippon GA; Klatt J; Xue F; Chia V; Zhang F; Cheng S; Mikol DD
    Cephalalgia; 2019 Oct; 39(11):1455-1464. PubMed ID: 31146544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
    Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
    Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.
    Pozo-Rosich P; Detke HC; Wang S; Doležil D; Li LQ; Aurora SK; Reuter U
    Curr Med Res Opin; 2022 May; 38(5):731-742. PubMed ID: 35392739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.